Non Metastatic clinical trials

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Virus therapy with chemo and immunotherapy for advanced lung cancer

This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.

Lung cancer testing and treatment outcomes research study platform

This study collects information from adults with different types and stages of lung cancer to connect molecular test results with treatment choices and outcomes. It may help improve how lung cancer is diagnosed and managed by building a better understanding of what works for different patients.

Study of Chemotherapy and Amivantamab for Advanced Lung Cancer

This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.

Blood methylation test to guide follow-up after colon cancer surgery

This study checks a special blood test (circulating tumor DNA methylation) to help guide follow-up after surgery for non-metastatic colon cancer. It may help find whether additional treatment or closer monitoring is needed based on the test results.

Liver artery chemotherapy for non-surgical bile duct cancer

This trial tests delivering two chemotherapy medicines directly into the liver’s artery in people with bile duct cancer inside the liver that cannot be removed with curative surgery. It aims to control the cancer after first-line treatment and see how well this targeted approach works.

Immune cells in non-spreading rectal cancer treatment

This study is looking at immune cells (NK cells and ImmunoScore) in the blood of people with rectal cancer that hasn't spread. It may help doctors learn more about how the immune system responds to standard chemoradiation treatment.

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations

OBX-115 cell therapy for advanced melanoma or lung cancer

This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.

Testing a live tumor test for immune therapy response

This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.

New drug plus chemotherapy for advanced lung cancer

This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.

Immune cell therapy for advanced lung cancer after chemotherapy

This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.

SBRT for lung cancer with limited new growth

This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.

DaRT radiation therapy for prostate cancer that has returned

This trial tests a new type of radiation using tiny alpha-emitting seeds placed directly into the tumor. It is for people whose prostate cancer came back in the gland after initial treatment but hasn't spread elsewhere.

Carfilzomib and sotorasib for KRAS G12C lung cancer

This trial tests a combination of two drugs: carfilzomib and sotorasib, for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have already tried a KRAS-targeting drug that stopped working. The goal is to see if this new combination can shrink tumors or slow the cancer.

Radioactive drug plus immunotherapy for FAP-positive lung cancer

This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.

Study of Dato-DXd with or without osimertinib for EGFR-mutated lung cancer

This trial tests a new drug, Dato-DXd, given alone or with osimertinib, versus standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after osimertinib treatment.

Nivolumab plus PBF-1129 for advanced lung cancer

This Phase 1 trial tests a new combination of PBF-1129 with nivolumab (an immune therapy) for lung cancer that has come back or spread. It aims to find a safe dose and see whether the combination can shrink tumors and improve outcomes.

Vismodegib and Atezolizumab for advanced lung cancer

This trial tests a combination of two drugs, vismodegib and atezolizumab, for people with non-small cell lung cancer that has spread or come back after standard treatments. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.

Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer

This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.

Visugromab plus standard chemo-immunotherapy for lung cancer

This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.

Diclofenac for advanced lung cancer on immunotherapy

This trial tests whether adding the anti-inflammatory drug diclofenac can help people with advanced non-small cell lung cancer whose tumors are growing while on a single immunotherapy drug. You must have been on immunotherapy for at least 12 weeks and have a growing tumor, but your doctor does not plan to change your treatment right away.

Sotorasib and trastuzumab deruxtecan for KRAS G12C lung cancer

This trial tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, for people with advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation. It may be an option if you've already had treatment with a KRAS G12C inhibitor, immunotherapy, and chemotherapy.

Darolutamide plus standard hormone therapy for high-risk prostate cancer

This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.